---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-086174"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:42:43.081420+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q2 revenue up 14% to $64.2M; net loss widens to $0.23/sh; guidance reaffirmed

## Summary
- Revenue $64.2M (+14% YoY, +18% constant currency); Biopharma/Pharma $51.7M (+14%).
- Net loss to common $11.2M ($0.23/sh) vs $7.4M ($0.16) in Q2 2021; GAAP net loss $9.2M.
- Adjusted EBITDA $6.0M, flat YoY; gross margin 45.0%, steady YoY and up 224bps sequentially.
- FY2022 revenue guidance reaffirmed at $260M-$265M; $33.3M share repurchase completed at avg $24.84.
- Record 626 clinical trials supported; opened new Global Supply Chain Centers; closed three acquisitions in Europe.

## SEC filing metadata
- accession: 0001104659-22-086174
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465922086174/0001104659-22-086174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465922086174/tm2222628d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-086174
- JSON: https://secwatch.observer/filing/0001104659-22-086174.json
- Plain text: https://secwatch.observer/filing/0001104659-22-086174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.